retatrutide ly3437943 parkinson's disease clinical trial Delivers Significant Hemoglobin A1C Reduction, Weight Loss in Phase 3 Type 2 Diabetes retatrutide parkinson's disease clinical trial

The most commonly reported adverse effects in Phase 2 trials were gastrointestinal in nature, including: Nausea (the most frequently reported) Vomiting Diarrhoea Constipation Decreased appetite These effects were generally dose-dependent and most pronounced during dose escalation, typically improving over time

Researchers believe that nausea/vomiting is related to greater weight loss (90)

Pan-fry 7 min on medium-high

The visual demonstration helps clarify complex topics and gives you a real-world perspective on implementation

Best practices include: Setting realistic expectations at initiation Documenting and tracking tolerability Adjusting or switching medications based on response Collaborating with dietitians and other care team members Supporting your patients through each stage of therapy leads to greater confidence and continuity